R.T. Abraham, et al., “Cellular Effects of Olomoucine, and Inhibitor of Cyclin-dependent Kinases” Biol. Cell, 1995, pp 105-120, vol. 83. |
D.W. Fry, et al., “Inhbitors of Cyclin-dependent Kinases as Therapeutic Agents for the Treatment of Cancer”, Curr. Opin. Oncol. Endo. Metabol. Invest. Drugs, 2000, pp 40-59, vol. 2, No. 1. |
G. Kaur, et al., “Growth Inhibition with Resversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275”, J. Natl. Can. Inst., Nov. 18, 1992, pp 1736-1740, vol. 84, No. 22. |
L. Meijer, “Chemical Inhibitors of Cyclin-dependent Kinases”, Prog. Cell Cycl. Res., 1995, pp 351-363, vol. 1. |
H. H. Sedlacek, et al., “Flavopiridol (L86 8275; NSC 649890), a New Kinase Inhibitor for Tumor Therapy”, Inter. J. Oncol., 1996, pp 1143-1168, vol. 9. |
L. Sun, et al., “Inhibition of Tumor Angiogenesis by Synthetic Receptor Tyrosine Kinase Inhibitors”, DDT, Aug. 8, 2000, pp 344-353, vol. 5, No. 8. |
J. Vesely, et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”, eUR. j. bIOCEHM., 1994, pp 771-786, vol. 224. |